无并发症急性B型主动脉夹层TEVAR时机与并发症的关联
基于VQI注册库2010–2019年688例无并发症急性B型主动脉夹层行TEVAR的回顾性分析,倾向性匹配后1–14天组与15–90天组各187例。匹配后两组死亡率与术后并发症无显著差异,但1–14天组30天和1年再干预率更高(15.3% vs 5.2%,P=.02;33.8% vs 14.5%,P=.007)。结论提示TEVAR时机不预测死亡或并发症,但早期修复与再干预风险升高相关。
要点
- 无并发症急性B型夹层TEVAR时机不预测术后死亡或并发症。
- 1–14天修复与30天及1年再干预率升高相关。
- 多变量分析未显示长期生存或再干预的显著差异。
核心结论
- 无并发症急性B型主动脉夹层TEVAR时机不预测死亡或术后并发症,但1–14天修复与再干预风险升高强相关。
研究设计与样本
- 回顾性分析Vascular Quality Initiative TEVAR与复杂EVAR注册库2010–2019年数据。
- 纳入688例无并发症急性B型主动脉夹层行TEVAR病例,排除非夹层疾病及伴灌注不良或破裂的夹层。
- 按症状发作至TEVAR时间分急性组(1–14天)与亚急性组(15–90天),倾向性匹配后每组各187例。
主要发现
- 匹配后两组术后死亡率、院内并发症及再干预无统计学显著差异。
- 单因素分析示1–14天组30天内再干预比例15.3%,高于15–90天组的5.2%(P=.02)。
- 1年再干预率1–14天组33.8%,15–90天组14.5%(P=.007)。
- 多变量分析示长期生存、并发症及长期再干预无统计学显著差异。
- 1–14天组院内再干预比值比为15–90天组的2.3倍,趋势接近显著(P=.08)。
临床怎么用
- 对无并发症急性B型夹层选择TEVAR时机时,需权衡早期修复与再干预风险升高。
- 1–14天修复者应加强术后再干预监测。
局限性
- 1–14天组可能代表解剖或生理风险 inherently 更高的群体,倾向性分析无法完全校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous publications have clearly established a correlation between timing of thoracic endovascular aortic repair (TEVAR) and complications after treatment of complicated acute type B aortic dissection (ATBAD). However, the temporal association of TEVAR with morbidity after uncomplicated presentations is poorly understood and has not previously been examined using real-world national data. Therefore, the objective of this analysis was to determine whether TEVAR timing of uncomplicated ATBAD (UATBAD) is associated with postoperative complications. METHODS: The Vascular Quality Initiative TEVAR and complex endovascular aneurysm repair registry was analyzed from 2010 to 2019. Procedures performed for non-dissection-related disease as well as for ATBAD with malperfusion or rupture were excluded. Because of inherent differences between timing cohorts, propensity score matching was performed to ensure like comparisons. Univariate and multivariable analysis after matching was used to determine differences between timing groups (symptom onset to TEVAR: acute, 1-14 days; subacute, 15-90 days) for postoperative mortality, in-hospital complications, and reintervention. RESULTS: A total of 688 cases meeting inclusion criteria were identified. After matching 187 patients in each of the 1- to 14-day and 15- to 90-day treatment groups, there were no statistically significant differences between groups. On univariate analysis, the 1- to 14-day treatment group had a higher proportion of cases requiring reintervention within 30 days (15.3%) compared with UATBAD patients undergoing TEVAR within 15 to 90 days (5.2%; P = .02). There was also a difference (P = .007) at 1 year, with 33.8% of the 1- to 14-day UATBAD patients undergoing reintervention compared with 14.5% for the 15- to 90-day group. There were no statistically significant differences on multivariable analysis for long-term survival, complications, or long-term reintervention. There was a trend toward significance (P = .08) with the 1- to 14-day group having 2.3 times the odds of requiring an in-hospital reintervention compared with the 15- to 90-day group. CONCLUSIONS: Timing of TEVAR for UATBAD does not appear to predict mortality or postoperative complications. However, there is a strong association between repair within 1 to 14 days and higher risk of reintervention. This may in part be related to the 1- to 14-day group's representing an inherently higher anatomic or physiologic risk population that cannot be entirely accounted for with propensity analysis. The role of optimal timing to intervention should be incorporated into future study design of TEVAR trials for UATBAD.
引用
- Torrent DJ, McFarland GE, Wang G, et al. Timing of thoracic endovascular aortic repair for uncomplicated acute type B aortic dissection and the association with complications. J Vasc Surg. 2020. PMID: 32623110. doi:10.1016/j.jvs.2020.05.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。